Real-World Alcohol Use Disorder Outcomes in PatientsWith Concurrent Metabolic Dy
A recent study shows that GLP-1 receptor agonists are associated with a 45% lower rate of one-year AUD relapse compared to naltrexone in patients with concurrent metabolic dysfunction.
GLP-1 Receptor Agonists: Metabolic Health Risks in Youth
Pancreatic fat accumulation is a key factor in metabolic dysfunction among youth. It independently predicts insulin resistance and cardiometabolic risk in obese children. Understanding this helps guide early intervention with GLP-1 receptor agonists.
GLP-1 Cardiovascular Outcomes: Metabolic Health Phenotypes
Metabolic health phenotypes influence cardiovascular outcomes beyond BMI alone. Understanding these phenotypes helps tailor GLP-1 therapy for better cardiometabolic risk management. This approach supports personalized treatment for patients with obesity…
GLP-1 Receptor Agonist Safety in Women’s Hormonal Health
GLP-1 receptor agonist hormonal safety is critical in women with PCOS and related conditions. These agents improve insulin sensitivity but require careful contraceptive counseling. Understanding hormonal safety helps optimize reproductive and metabolic…
GLP-1 Receptor Agonist Clinical Evidence on Optimal Body Fat
This article reviews optimal body fat clinical evidence related to GLP-1 receptor agonist therapy. Understanding body composition is crucial for managing fat loss and metabolic health. Clinicians should focus on preserving lean mass alongside fat…
Cannabidiol and Cannabigerol Ameliorate Steatotic Liver Disease
Cannabidiol and cannabigerol fatty liver effects show promise in improving metabolic liver disease. These cannabinoids work through phosphocreatine buffering and lysosomal restoration. This study highlights their potential therapeutic roles in steatotic…